Ts of both sexes had been enrolled within the study if they met the following inclusion criteria: 18 years and older, COVID-19 diagnosis confirmed by detection of SARS-CoV-2 precise ribonucleic acid (RNA) in nasopharyngeal swabs applying quantitative 16 GPCR/G Protein polymerase chain reaction (qPCR), respiratory distress (30 breaths per minute), hypoxia (peripheral oxygen saturation 92 on room air), or 50 lung involvement on imaging. Individuals had been excluded in the study if they had a earlier diagnosis of human immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis B virus (HBV), cancer, endocrine disorders, or autoimmune disease. Pregnant or lactating women and patients below long-term immunomodulatory medication, like non-steroidal anti-inflammatory drugs, had been also excluded from the study. All study participants provided written informed consent previously approved by the institutionalMicroorganisms 2021, 9,3 ofethical committee of the Basic Hospital of Mexico (registration variety of the ethical code approval: DI/20/501/03/17). The study rigorously met the principles described inside the 1964 Declaration of Helsinki and its posterior amendment in 2013. This cross-sectional study met the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: suggestions for reporting observational research. two.2. Data Collection We collected demographic and clinical information from the Emergency Division on the General Hospital of Mexico at admission. We also recorded clinical evolution, drug regimen, and inpatient days up to hospital discharge or death. Demographic and clinical information integrated sex, age, and previous diagnosis of obesity (body mass index (BMI) 30 kg/m2), kind 2 diabetes (T2D), hypertension, Toceranib phosphate Cancer coronary heart disease (CHD), chronic kidney disease (CKD), and chronic liver illness (CLD). two.3. Laboratory Parameters We collected laboratory information at admission working with the digital version of the electronic wellness record of the Basic Hospital of Mexico. Laboratory parameters incorporated albumin, blood glucose, lipid profile, liver function tests, kidney function tests, coagulation markers, hematic biometry, CRP, troponin I, ferritin, procalcitonin, myoglobin, and D-dimer. We measured all laboratory parameters within sixty minutes of the patient’s arrival in the hospital applying the Beckman Coulter DxC 700 AU Chemistry Analyzer (Beckman Coulter Inc., Brea, CA, USA), the Coulter LH 780 Hematology Analyzer (Beckman Coulter Inc., Brea, CA, USA), and also the BCSXP Method (Siemens Healthcare GmbH, Erlangen, Germany), following common operating procedures. 2.four. IL-15 Serum Levels At hospital admission, four mL blood samples had been drawn from all participants and collected in pyrogen-free tubes (VacutainerTM , BD Diagnostics, NJ, USA) at area temperature. Just after a centrifugation step at 1000 g/4 C for 30 min, we obtained serum samples for measuring IL-15 in triplicate by the Enzyme-Linked ImmunoSorbent Assay (ELISA) (PeproTech, Cranbury, NJ, USA). We measured IL-15 serum levels within 180 min on the patient’s arrival within the hospital. two.5. Statistics We collected all demographic, clinical, laboratory, and immune parameters at hospital admission. We followed up with sufferers until hospital discharge or death. Then, we formed two groups of sufferers according to the major outcome: survival or non-survival. Within this way, we analyzed and compared all demographic, clinical, and laboratory parameters retrospectively. We applied the Shapiro ilk test to estimate the n.
